is this new article the reason for the Renewed Interest,,,in SIGA?
Biotech Companies Attractive Targets for Pharmaceutical Companies Looking to Replace Lost Revenues
Five Star Equities Provides Stock Research on OXiGENE and SIGA Technologies
Press Release: Five Star Equities – 1 hour 20 minutes ago.. .
NEW YORK, NY--(Marketwire - Feb 8, 2013) - Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years. A total of 676 takeovers of biotechnology and pharmaceutical companies have occurred in the past three years, with an average premium of 38 percent, according to data collected by Bloomberg. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on OXiGENE, Inc. ( NASDAQ : OXGN ) and SIGA Technologies, Inc. ( NASDAQ : SIGA ).
Another of interest:
ASM to host 2013 Biodefense and Emerging Diseases Research Meeting from Feb. 25-27
The American Society for Microbiology (ASM) will host its 2013 Biodefense and Emerging Diseases Research Meeting February 25-27, 2013 at the Marriott Wardman Park Hotel in Washington, DC.
The purpose of this meeting is to bring together individuals who are carrying out research to defend against the threat of bioterrorism with decision makers shaping the future biodefense research agenda, recognizing that emerging infectious diseases serve as a paradigm for handling the public threat of bioterrorism.
This meeting is intended for scientists, public health researchers and policy makers who need to be informed about the latest scientific developments. The meeting will include a series of keynote addresses by leaders in the field of biodefense and poster sessions presenting up-to-the-minute cutting-edge research on biothreat agents, vaccines, detection and diagnostic procedures, animal and plant pathogens, global surveillance, and other vital topics.
Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression. OXiGENE shares surged after reporting a combination of ZYBRESTAT and Avastin have continued to be well tolerated in a second interim and final toxicity analysis of a Phase 2 ovarian cancer trial.
SIGA Technologies specializes in the development and commercialization of pharmaceutical solutions for some of the most lethal disease-causing pathogens in the world -- smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. The company has announced that their smallpox antiviral will now be branded as Arestvyr (previously ST-246) for all purposes.